Radiohalogen Prosthetic Moieties for Stable Radiolabeled Biomolecules
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional radioiodinated biomolecules, such as antibodies and peptides, face instability in vivo due to proteolysis and deiodination, leading to loss of radioactivity from tumor cells and increased uptake in normal tissues, resulting in low tumor-to-background ratios and limited delivery to brain tumors due to their size and long half-life in the bloodstream.
Innovation Solution
Development of radiohalogen prosthetic moieties and precursors for radiolabeling biomolecules with radioactive iodine, which minimize dehalogenation in vivo, preserve biological activity, and maximize retention in cancer cells, using polydentate chelate moieties like DOTA and NOTA, and macromolecule conjugation moieties for targeted radiotherapy and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional radioiodinated biomolecules are used, then radioactivity can be introduced into biomolecules, but the radioactivity is lost from tumor cells due to proteolysis and deiodination
Solution Approach 1:
The patent introduces a prosthetic moiety as an intermediary component between the radioactive iodine and the biomolecule. This prosthetic moiety contains a polydentate chelate that binds the radioactive iodine and a conjugation component that attaches to the biomolecule, creating a stable bridge that prevents both proteolysis and deiodination while maintaining radioactivity retention in tumor cells
Solution Approach 2:
The invention creates a composite radiolabeled biomolecule structure consisting of three components: the biomolecule itself, a prosthetic moiety with polydentate chelate, and radioactive iodine. This composite structure provides enhanced stability against proteolysis and deiodination compared to direct radioiodination, while maintaining the targeting capability of the biomolecule
2Reliability
If antibodies are used for tumor targeting, then specific binding to tumor cells is achieved, but the long half-life in bloodstream results in high background levels
Solution Approach 1:
The patent segments the traditional antibody structure into smaller fragments such as scFv, Fab, or Fv regions that retain tumor-specific binding capability. These smaller fragments have reduced molecular weight leading to faster clearance from the bloodstream and lower background levels, while maintaining the ability to specifically bind tumor cells through their antigen-binding sites
3Reliability
If conventional antibodies are used, then tumor targeting is achieved, but slow diffusion into solid tumors prevents homogeneous distribution
Solution Approach 1:
By segmenting the antibody into smaller fragments (scFv, Fab, Fv), the patent reduces the hydrodynamic radius and molecular weight of the targeting agent. This segmentation enables faster penetration and diffusion into solid tumor tissue, allowing more homogeneous distribution throughout the tumor mass while retaining the ability to bind tumor-specific antigens
4Ease of operation
If antibodies are used for brain tumor treatment, then systemic administration is possible, but low uptake into brain metastases occurs due to size and blood-brain barrier restrictions
Solution Approach 1:
The patent employs segmented antibody fragments with reduced molecular size that can more effectively navigate the blood-brain barrier through passive diffusion or receptor-mediated transport mechanisms. These smaller fragments maintain tumor-targeting specificity while achieving improved penetration into brain metastases compared to full-length antibodies
5Ease of manufacture
If radioiodination is performed, then biomolecules can be radiolabeled, but deiodination occurs leading to increased uptake in normal tissues
Solution Approach 1:
The prosthetic moiety acts as a protective intermediary between the radioactive iodine and the biomolecule. The polydentate chelate within the prosthetic moiety forms a stable complex with the radioactive iodine, preventing deiodination and subsequent redistribution to normal tissues, while the conjugation component ensures proper positioning on the biomolecule for effective tumor targeting
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances the retention of radioactivity in cancer cells while minimizing normal tissue uptake, improving tumor targeting and delivery, especially to brain metastases by stabilizing the radiolabeled biomolecules and optimizing their size for effective imaging and therapy.
Implementation Method 1
MC is a polydentate chelate moiety
Implementation Method 2
The biomolecules have an affinity for particular types of cells. That is, the biomolecules may specifically bind a certain cell, such as a cancer cell
Data Source
AI summary
The application is drawn to radiohalogen prosthetic moieties and precursors thereof and to radiolabeled biomolecules comprising such radiohalogen prosthetic moieties. The biomolecules have an affinity for particular types of cells and may specifically bind a certain cell, such as a cancer cell. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles, aptamers, and pharamacological moieties used to target prostate-specific membrane antigen (PSMA).